Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
87P - Assessment of the prognostic utility of the enumeration of circulating tumour cells at the end of treatment and disease relapse in small cell lung cancer patients (ID 612)
12:30 - 13:00 | Author(s): C. Dive
Small cell lung cancer (SCLC) is an aggressive cancer characterised by early invasion and metastasis, the rapid emergence of treatment resistance and poor prognosis. Previous research has demonstrated that the number of circulating tumour cells (CTCs) at baseline is prognostic in SCLC, associated with poorer overall survival (OS). Our aim was to explore the prognostic utility of the quantification of CTCs at the end of treatment (EoT) and the development of disease relapse, in addition to baseline.
This was a single-centre study assessing CTC numbers in 105 patients with SCLC recruited to a lung cancer biomarker programme between 2009 and 2017. CTC enumeration was performed with CellSearch™ at baseline and at least one further timepoint including EoT, 1[st] or 2[nd] disease relapse. Clinical data was extracted from the electronic patient records database. Data was analysed for trends between CTC number and progression free (PFS) and OS.
Baseline measurements were stratified into groups of ≥50 and <50 CTCs/7.5 ml. Patients in the ≥50 CTCs/7.5 ml group had significantly lower mean PFS (9.6 vs 5.8 months, p < 0.05) and OS (14.4 vs 9.3 months, p < 0.05). EOT CTCs were significantly lower than at baseline (mean = 73 vs 632 CTCs/7.5 ml, p < 0.05) and lower than 1[st] (mean = 202 CTCs/7.5 ml) and 2[nd] (mean = 602 CTCs/7.5 ml) relapse. EOT CTCs were split into groups of 0, 1–20 and >20 CTCs/7.5 ml. Patients in the >20 CTCs/7.5 ml group had the shortest PFS (mean = 4.6 months) and significantly shorter OS (mean = 5.6 months, p < 0.05) compared to those with less CTCs. The same CTC groups were used for the 1[st] relapse, with decreasing mean PFS (3.9 vs 6.8 months) and OS (10.1 vs 17.1 months) as patients moved from the most to the least favourable groups.
This study indicates that EoT CTC number may be predictive of both PFS and OS. We also noted a negative correlation between relapse CTC numbers and survival times, but further research is required to determine the statistical significance of this relationship. With further work, CTCs may have a role in evaluating response to treatment and monitoring for relapse.
Clinical trial identification:
Legal entity responsible for the study:
The Christie NHS Foundation Trust
Has not received any funding
All authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.